On September 11, 2023, Dianthus Therapeutics, Inc. closed the transaction. The company has received $71.987749 million private investment for the issuance of 2,873,988 common stock at a purchase price $23.34 per share for a gross proceeds $67.07888 million and 210,320 pre-funded warrants at a purchase price $23.34 per warrant for a gross proceeds of $4.908869 million in the transaction.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25.53 USD | -1.28% | +1.07% | +145.48% |
12/06 | Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy | MT |
12/06 | Dianthus Therapeutics Gets FDA Clearance for DNTH103 Phase 2 Trial | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+145.48% | 75Cr | |
+16.73% | 12TCr | |
+21.13% | 11TCr | |
+18.05% | 2.59TCr | |
-17.94% | 2.09TCr | |
-16.24% | 1.65TCr | |
-11.76% | 1.68TCr | |
-44.45% | 1.56TCr | |
+69.92% | 1.55TCr | |
+1.41% | 1.34TCr |
- Stock Market
- Equities
- DNTH Stock
- News Dianthus Therapeutics, Inc.
- Dianthus Therapeutics, Inc. announced that it has received $71.987749 million in funding from a group of investors